Replies to post #59102 on NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

Thanks Doc. I thought perhaps RT and Chemo might have had an immuno-suppressive effect.
The study shows that a high TIL score is only linked to improved outcome when DCVax is employed.

According to this study by Rutledge et al.:-

"TILs were enriched in glioblastomas of the mesenchymal class, strongly associated with
mutations in NF1 andRB1 and typical of histologies characterized by these mutations. Conversely, TILs were
depleted in the classical class, EGFR-amplified, and homozygous PTEN-deleted tumors and rare in
histologies characterized by these alterations."

http://clincancerres.aacrjournals.org/content/early/2013/08/29/1078-0432.CCR-13-0551.full.pdf

Confirms what we know that DCVax represents an effective cure for those in the mesenchymal transcriptional class.

And given that 30-50% of GBM are mesenchymal, and taking Flip's comments about enhanced dosing in Phase 3, I remain confident that the trial will comfortably meet the required 4 month extension in PFS.